Evaluation of the drug–drug interaction between triazole antifungals and cystic fibrosis transmembrane conductance regulator modulators in a real-life cohort-Reference-Cited by-同舟云学术

Evaluation of the drug–drug interaction between triazole antifungals and cystic fibrosis transmembrane conductance regulator modulators in a real-life cohort

Published:2024-03 Issue:3 Volume:62 Page:
ISSN:1369-3786
Container-title:Medical Mycology
language:en
Short-container-title:

Author:

Jansen Anouk M E¹²^ORCID,Eggermont Margot N³,Wilms Erik B⁴^ORCID,Aziz Sami¹,Reijers Monique⁵,Roukema Jolt⁶,Warris Adilia⁷,Brüggemann Roger J M¹²,van der Meer Renske³

Affiliation:

1. Department of Pharmacy, Radboud university medical center, Radboud Institute for Medical Innovations , Nijmegen , the Netherlands

2. Radboud university medical center-Canisius Wilhelmina Ziekenhuis Center of Expertise for Mycology , Nijmegen , The Netherlands

3. Department of Pulmonology and Adult CF Centre, Haga Teaching Hospital , The Hague , Netherlands

4. Apotheek Haagse Ziekenhuizen (AHZ) and Department of Pharmacy, Haga Teaching Hospital , The Hague , Netherlands

5. Department of Pulmonology, Radboud university medical center, Radboud Institute for Medical Innovations , Nijmegen , the Netherlands

6. Department of Paediatrics, Radboud university medical center, Amalia Children's Hospital, Radboud Institute for Medical Innovations , Nijmegen , the Netherlands

7. MRC Centre for Medical Mycology, University of Exeter , Exeter , United Kingdom

Abstract

Abstract Limited data on the clinical management of drug–drug interactions between triazoles and Cystic Fibrosis transmembrane conductance regulator (CFTR) modulators are available. We retrospectively evaluated azole target attainment and dose adaptations in patients from two Dutch CF centres concomitantly receiving triazoles and CFTR modulators. In total, 21 patients with 59 triazole trough concentrations were evaluated. Subtherapeutic concentrations were frequently observed, especially for itraconazole and voriconazole. Of the investigated antifungal agents, posaconazole appears the most preferable option. Our results emphasize the importance of adequate management of this interaction and underpin the added value of therapeutic drug monitoring of triazoles in this population.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/mmy/advance-article-pdf/doi/10.1093/mmy/myae020/56874049/myae020.pdf

Reference17 articles.

1. Clinical characteristics of Pseudomonas and Aspergillus co-infected cystic fibrosis patients: A UK registry study;Hughes;J Cyst Fibros,2022

2. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis;Mastella;Eur Respir J,2000

3. Aspergillus Infections and Progression of Structural Lung Disease in Children with Cystic Fibrosis;Breuer;Am J Respir Crit Care Med,2020

4. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis;Amin;Chest,2010

5. Progress in therapies for cystic fibrosis;De Boeck;Lancet Respir Med,2016